IDEAS home Printed from https://ideas.repec.org/a/epw/ejmed0/v3y2021i4id40960.html

Anti-Lethal Therapy of COVID-19 for Home Health Outpatient Therapy

Author

Listed:
  • Oleg Bukhtoyarov

    (Medical Center 39 Ltd, Russian Federation)

  • Denis Samarin

    (Medical Center 39 Ltd, Russian Federation)

Abstract

The article presents the rationale for a new therapeutic strategy for treatment of patients with COVID-19, based on the combined use of biologic response modifiers and drugs targeting etiology and pathophysiology of the novel coronavirus infection, excluding disadvantages of polypharmacy, and providing a high clinical effect. This approach has been predominantly used in home health outpatient treatment of 324 patients with COVID-19 of variable severity using the biologic response modifiers “double drug cocktail” made of recombinant human interleukin-2 and recombinant human interferon alpha-2b in combination with alimemazine, nimesulide, rivaroxaban and antibiotic therapy (co-amoxiclav, or ceftriaxone) if secondary bacterial pneumonia was diagnosed. The results obtained indicate a dramatic improvement in the condition of patients, even with a severe COVID-19, which made possible to avoid artificial ventilation and prevent deaths.

Suggested Citation

  • Oleg Bukhtoyarov & Denis Samarin, 2021. "Anti-Lethal Therapy of COVID-19 for Home Health Outpatient Therapy," European Journal of Medical and Health Sciences, European Open Science, vol. 3(4), pages 73-79, July.
    • Handle: RePEc:epw:ejmed0:v:3:y:2021:i:4:id:40960
    DOI: 10.24018/ejmed.2021.3.4.960
    as

    Download full text from publisher

    File URL: https://eu-opensci.org/index.php/ejmed/article/view/40960
    File Function: Abstract page
    Download Restriction: no
    File URL: https://eu-opensci.org/index.php/ejmed/article/download/40960/9304
    File Function: Full text
    Download Restriction: no
    File URL: https://libkey.io/10.24018/ejmed.2021.3.4.960?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Keywords

    ;
    ;
    ;
    ;
    ;
    ;

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:epw:ejmed0:v:3:y:2021:i:4:id:40960. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Support (email available below). General contact details of provider: https://eu-opensci.org/index.php/ejmed .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.